Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: A retrospective analysis of the Intergroup Exemestane Study

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages 420-432

  Mieog, J Sven D ^a   Morden, James P ^b   Bliss, Judith M ^b   Coombes, R Charles ^c   Van de Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BODY WEIGHT; BREAST CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CARPAL TUNNEL SYNDROME; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG USE; DRUG WITHDRAWAL; EARLY CANCER; FEMALE; FOLLOW UP; GEOGRAPHY; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; INCIDENCE; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOARTHRITIS; OVARIECTOMY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK FACTOR; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARPAL TUNNEL SYNDROME; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL ABNORMALITIES; POSTMENOPAUSE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84859159091     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70328-X     Document Type: Article

References (24)

1. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
2. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
3. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
4. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776.
5. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
6. Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol 2011, published online Nov 21. 10.1200/JCO.2010.33.7899.
7. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34:275-282.
8. Burstein HJ Aromatase inhibitor-associated arthralgia syndrome. Breast 2007, 16:223-234.
9. Sestak I, Sapunar F, Cuzick J Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009, 27:4961-4965.
10. Bland JD Carpal tunnel syndrome. BMJ 2007, 335:343-346.
11. Singh R, Gamble G, Cundy T Lifetime risk of symptomatic carpal tunnel syndrome in type 1 diabetes. Diabet Med 2005, 22:625-630.
12. Palumbo CF, Szabo RM, Olmsted SL The effects of hypothyroidism and thyroid replacement on the development of carpal tunnel syndrome. J Hand Surg 2000, 25:734-739.
13. Atroshi I, Englund M, Turkiewicz A, et al. Incidence of physician-diagnosed carpal tunnel syndrome in the general population. Arch Intern Med 2011, 171:943-944.
14. Gelfman R, Melton LJ, Yawn BP, et al. Long-term trends in carpal tunnel syndrome. Neurology 2009, 72:33-41.
15. Cuzick J, Sestak I, Cella D, et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148.
16. Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124.
17. Llombart-Cussac A, Ruiz A, Anton A, et al. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. Cancer 2011, published online June 29. 10.1002/cncr.26299.
18. Pascual E, Giner V, Arostegui A, et al. Higher incidence of carpal tunnel syndrome in oophorectomized women. Br J Rheumatol 1991, 30:60-62.
19. Bjorkqvist SE, Lang AH, Punnonen R, et al. Carpal tunnel syndrome in ovariectomized women. Acta Obstet Gynecol Scand 1977, 56:127-130.
20. Cannon LJ, Bernacki EJ, Walter SD Personal and occupational factors associated with carpal tunnel syndrome. J Occup Med 1981, 23:255-258.
21. Toesca A, Pagnotta A, Zumbo A, et al. Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int 2008, 32:75-79.
22. Claassen H, Hassenpflug J, Schunke M, et al. Immunohistochemical detection of estrogen receptor alpha in articular chondrocytes from cows, pigs and humans: in situ and in vitro results. Ann Anat 2001, 183:223-227.
23. Richette P, Corvol M, Bardin T Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 2003, 70:257-262.
24. Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008, 26:3147-3152.